Advertisement

Gliomas

  • Robert Jenkins
Chapter

Abstract

More than 18,000 people were diagnosed with and more than 13,000 died from primary brain tumors in 2003.1 The most common of the primary brain tumors is gliomas. Depending on the grade and morphologic type of glioma, newly diagnosed patients receive watchful waiting, surgical resection, radiotherapy, or chemotherapy, or some combination of these therapies. Regardless of therapy, most patients will progress and have a high risk of mortality and reduced quality of life. Thus, there has been intense interest in understanding the biology and genetics of gliomas, to provide better diagnostic tools and new therapeutic approaches. Molecular pathology markers are being identified that have been or will soon prove to be clinically useful in the practice of clinical neurooncology (see Table 27-1).

Keywords

Epidermal Growth Factor Receptor Glioblastoma Multiforme TP53 Mutation Anaplastic Astrocytoma Astrocytic Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26.PubMedGoogle Scholar
  2. 2.
    Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–225.PubMedGoogle Scholar
  3. 3.
    Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol. 1999;1:44–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000;59:495–503.PubMedGoogle Scholar
  5. 5.
    Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci. 2000;5:D213–D231.PubMedCrossRefGoogle Scholar
  6. 6.
    Kitange GJ, Smith JS, Jenkins RB. Genetic alterations and chemotherapeutic response in human diffuse gliomas. Expert Rev Anticancer Ther. 2001;1:595–605.PubMedCrossRefGoogle Scholar
  7. 7.
    Lin H, Bondy ML, Langford LA, et al. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998;4:2447–2454.PubMedGoogle Scholar
  8. 8.
    Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–1256.PubMedCrossRefGoogle Scholar
  9. 9.
    Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patient with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95:651–659.PubMedGoogle Scholar
  10. 10.
    Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94:2688–2697.PubMedCrossRefGoogle Scholar
  11. 11.
    Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol. 2002;58:107–114.PubMedCrossRefGoogle Scholar
  12. 12.
    Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122–1128.PubMedGoogle Scholar
  13. 13.
    Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60:1383–1387.PubMedGoogle Scholar
  14. 14.
    Feldkamp MM, Roncari L, Lau N, Salhia B, Guha A. Expression of EGFRvIII is a better prognostic marker for GBM than either EGFR expression or the Ki-67 labeling index. Neuro-oncol. 2002;4:343.Google Scholar
  15. 15.
    Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H. Genetic profile of the giant cell glioblastoma. Lab Invest. 1999;79:123–129.PubMedGoogle Scholar
  16. 16.
    Kosel S, Scheithauer BW, Graeber MB. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery. 2001;48:187–193.PubMedCrossRefGoogle Scholar
  17. 17.
    Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev. 2000;26:67–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Kraus JA, Glesmann N, Beck M, et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol. 2000;48:89–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Kraus JA, Wenghoefer M, Glesmann N, et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol. 2001;52:263–272.PubMedCrossRefGoogle Scholar
  20. 20.
    Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer. 2002;95:249–257.PubMedCrossRefGoogle Scholar
  21. 21.
    Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013–2021.PubMedGoogle Scholar
  22. 22.
    Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144–4152.PubMedCrossRefGoogle Scholar
  23. 23.
    Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002;161:313–319.PubMedGoogle Scholar
  24. 24.
    Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473–1479.PubMedCrossRefGoogle Scholar
  25. 25.
    Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636–645.PubMedGoogle Scholar
  26. 26.
    Burger PC, Pearl DK, Aldape K, et al. Small cell architecture—a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol. 2001;60:1099–1104.PubMedGoogle Scholar
  27. 27.
    Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359–367.PubMedGoogle Scholar
  28. 28.
    Sanson M, Leuraud P, Aguirre-Cruz L, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg. 2002;97:1397–1401.PubMedCrossRefGoogle Scholar
  29. 29.
    Randazzo L, Scarpace L, Lemke N, et al. Tumoral and chromosomal heterogeneity in oligodendrogliomas detected with medium-throughput 1p/19q LOH analysis. Neuro-oncol. 2002;4:346.Google Scholar
  30. 30.
    Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 1988;48:405–411.PubMedGoogle Scholar
  31. 31.
    Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158:1253–1262.PubMedGoogle Scholar
  32. 32.
    Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol. 2002;23:61–69.PubMedCrossRefGoogle Scholar
  33. 33.
    Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res. 2001;61:1825–1829.PubMedGoogle Scholar
  34. 34.
    Mischel PS, Shai R, Choe GY, et al. Identification of distinctive subtypes of primary glioblastoma multiforme by gene expression profiling. Neuro-oncol. 2002;4:330.Google Scholar
  35. 35.
    Nutt CL, Mani DR, Betensky RA, et al. An accurate microarray class prediction model for high grade gliomas. Neuro-oncol. 2002;4:345.Google Scholar
  36. 36.
    Misra A, Pellarin M, Moore D, et al. A high-resolution genome wide map of genetic aberrations in human astrocytoma. Neuro-oncol. 2002;4:330.Google Scholar
  37. 37.
    Brennan C, Kim H, Cauwels C, et al. Identification of candidate genetic alterations from array-CGH in human glioblastomas. Neurooncol. 2002;4:327.Google Scholar
  38. 38.
    Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62:3335–3339.PubMedGoogle Scholar
  39. 39.
    Sausville EA, Elsayed Y, Monga M, Kim G. Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol. 2003;43: 199–231.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Robert Jenkins
    • 1
  1. 1.Department of Pathology and Laboratory MedicineMayo ClinicRochesterUSA

Personalised recommendations